Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

Abstract Background Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart size and function assessed by echocardiography during long ter...

Full description

Bibliographic Details
Main Authors: Alberto M. Marra, Michael Halank, Nicola Benjamin, Eduardo Bossone, Antonio Cittadini, Christina A. Eichstaedt, Benjamin Egenlauf, Satenik Harutyunova, Christine Fischer, Henning Gall, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Tobias J. Lange, Karen M. Olsson, Hans Klose, Ekkehard Grünig
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Respiratory Research
Subjects:
Pulmonary hypertension
Pulmonary arterial hypertension
Chronic thromboembolic pulmonary hypertension
Riociguat
Soluble guanylate cyclase stimulator
Right atrial area
Online Access:http://link.springer.com/article/10.1186/s12931-018-0957-y

Internet

http://link.springer.com/article/10.1186/s12931-018-0957-y

Similar Items